Method of predicting risk of thyroid gland diseases in women of perimenopausal age |
|
|
IPC classes for russian patent Method of predicting risk of thyroid gland diseases in women of perimenopausal age (RU 2421127):
 Method for prediction of developing metastases in patietns suffering rectal cancer / 2420742
Tissue samples of an tumour and perifocal regions are recovered from the preparation removed intraoperatively. They are analysed for the contents of prolactin and testosterone by radioimmunoassay. If the prolactin concentration is 692.0 ng/g of tissue, and the testosterone concentration is 48.0 ng/g of tissue in the tumour, while the testosterone concentration is 42.0 ng/g of tissue in the perifocal region, developing hepatic metastases are expected in 3 months. If the prolactin concentration is 160-390 ng/g of tissue, and the testosterone concentration is 20-40 ng/g of tissue in the tumour, while the testosterone concentration is 24-26 ng/g of tissue in the perifocal region, developing metastases are expected in 29-43 months.
 Diagnostic technique for function-type oddi's sphincter dyssynergia following cholecystectomy / 2416802
Cholecystokinin level is counted additionally in the patients with post-cholecystectomy syndrome. In case the concentration is below 0.5 ng/ml, and while observing no organic pathology of hepatopancreatoduodenal organs as demonstrated by instrument methods, function-type Oddi's sphincter dyssynergia is diagnosed.
Method of predicting duration of recurrence-free period in radically treated patients with mammary gland cancer / 2413231
Content of sex hormones -estradiol and progesterone - in blood is determined. After that coefficient of ratio of estradiol concentration to progesterone concentration is calculated. If values of coefficient are within the range from 10 to 221, duration of recurrence-free period from 5 to 13 years is predicted, and if values of coefficient are within the range 367-1295 recurrence-free period for 28-30 months is predicted.
Method of predicting of process activation in patients with hodgkin's lymphoma / 2405454
Invention relates to medicine, namely to biochemical investigations in oncology, and can be used in determination of activation or stabilisation of pathologic process in patients with primary-resistant Hodgkin's lymphoma. In patients with primary-resistant Hodgkin's lymphoma at stages of treatment, by radioimmune method determined is content in blood of thyroid gland hormones - triiodothyronine and thyroxine, and adrenocortical hormone - cortisol, their concentration is summed up and in case of total level of hormones is within 278.2 nmole/l - 0 333.0 nmole/l conclusion about activation of malignant process is made, if total level of said hormones is 432.4 nmole/l - 833.2 nmole/l conclusion about absence of process activation is made.
Diagnostic technique for severity level of varicocele and its recuring / 2403871
Invention refers to medicine, namely to urology and vascular surgery. The sex hormones level in an involved vein is considered to be a criterion of the severity level of varicocele. There are evaluated the following sex hormones: testosterone, estradiol, progesterone simultaneously in the pampiniform plexus veins of a left ovary and in the peripheral vein of a bend of elbow, with determining the ratio of the sex hormones level in a healthy vein of the bend of elbow to the varicocele-involved pampiniform plexus vein. If said ratio of the sex hormones level is 1:10 to 1:50, the first degree of varicocele is diagnosed. Recurrent varicocele and the second degree of varicocele is diagnosed by the ratio of the sex hormones level in the healthy and involved veins 1:50 to 1:100 times (i.e. hormones concentration in a varicose vein is increased in tens times). If observing the ratio of the sex hormones level in the healthy vein and the involved vein of the pampiniform plexus veins of the left ovary increasing more than in 1:100, the third degree of varicocele is diagnosed. Surgical intervention is indicated if the ratio of the sex hormones level is diagnosed more than 1:50.
 Method of bone resorption to remodelling analysis / 2403870
Invention refers to medicine, namely to biochemistry, surgery and dentistry. The bone resorption to remodeling analysis is based on the biochemical blood examination. An the blood coefficient K1 is calculated by formula: K1=[(PTH:A)+(TNF-α:B)+(IL-1β:C)]:3, where PTH is the parathyroid hormone concentration (pg/ml) in the patients, A is the same value in healthy individuals, TNF-α is the level of tumor necrosis factor -α (pg/ml) in the patients, B is the same value in healthy individuals, IL-1β is the interleukin-1β concentration (pg/ml) in the patients, C is the same value in healthy individuals to derive the blood coefficient K2 by formula: K2=[(calcitonin: D) + (osteocalcin: E)]:2, where the calcitonin concentration (ng/ml) in the patients, D is the same value in healthy individuals, the osteocalcin level (ng/ml) in the patients, E is the same value in healthy individuals. Then the bone metabolism control coefficient (BMCC) is calculated by formula BMCC=K1:K2, and the higher BMCC than 1.17, the more intensive resorption prevails over remodelling; and the lower BMCC than 0.83, the more intensive remodelling prevails over resorption.
Method for assessment of kidney function in felines by measurement of ghrelin hormone levels / 2403573
Method for assessment of kidney function in felines includes determination of observed level of ghrelin in tissue or biofluid of feline and establishment of direct dependence of observed level of ghrelin on kidney function by comparison of observed level of ghrelin with reference level of ghrelin that characterises normal kidney function. Method for diagnostics of kidney disease in felines includes detection of observed level of ghrelin in tissue or biofluid of feline and comparison of observed ghrelin level with referent level of ghrelin, which characterises normal kidney function, where observed level lower than reference level indicates kidney disease or predisposition to it. Method for detection of kidney disease beginning in felines includes monitoring level of ghrelin in tissue or biofluid of feline for a certain period of time; where beginning is identified, if at any moment of time level of ghrelin decreases compared to initial level that characterises healthy kidney function. Diagnostics set includes (a) one or more test materials to detect observed levels of ghrelin in tissue or biofluid of feline; and (b) one or more user-available mediums bearing the following information: (i) reference level of ghrelin that corresponds to a specific feline; and (ii) algorithm of direct dependence of observed ghrelin level relative to reference level on kidney function or reverse dependence of observed ghrelin level relative to reference level on availability of kidney disease or predisposition to kidney disease.
Diagnostic technique for foetal maturity / 2399058
There are determined daily excretion of progesterone metabolite - pregnandiol (Pd), foetal steroids - 16α-hydroxy-ethiocholanolone (16α-OH-Et), 16α-hydroxy-androsterone (16α-OH-An), 16α-hydroxy-dihydroepiandrosterone (16α-OH-DHEA) and oestradiol (Oe) in pregnant women on their 37-42 weeks of pregnancy by capillary gas chromatography. A mature foetus is indicated by the following indices: daily Pd excretion is 150.4-348.3 mcmol/24 hour, 16α-OH-Et - 7.9-16.9 mcmol/24 hour, 16α-OH-An - 6.4-12.6 mkmol/24 hour, 16α-OH-DHEA - 15.4-26.1 mcmol/24 hour, Oe - 24.0-38.7 mcmol/24 hour, while an immature foetus show the indices as follows: daily Pd excretion 80.1-150.2 mcmol/24 hour, 16α-OH-Et - 5.8-7.8 mcmol/24 hour, 16α-OH-An - 4.6-6.3 mcmol/24 hour, 16α-OH-DHEA - 10.2-15.3 mcmol/24 hour, and Oe - 14.5-15.6 mcmol/24 hour, and in a overmature foetus, daily Pd excretion, 16α-OH-Et, 16α-OH-An, 16α-OH-DHEA and Oe are considerably lowered and are less than 50.0 mcmol/24 hour, less than 12.0 mcmol/24 hour, less than 5.8 mcmol/24 hour, less than 4.6 mcmol/24 hour, less than 10.2 mcmol/24 hour, respectively.
Method for prediction of clinical course in disseminated skin melanoma patients / 2399057
Method is implemented by blood analysis for total and free triiodothyronine after the termination of integrated treatment to derive the total to free triiodothyronine ratio, and it is within the range 0.26-0.31, steady state is predicted to be kept in the patients; the ratio within the range 0.19-0.22 ensures to predict the disease generalisation. Technical and economic efficiency of the invention consists in the fact that the derived prognosis factor is an informative laboratory covariant of the favourable or unfavourable development of the pathology.
Method for prediction of effectiveness of neoadjuvant automyelochemotherapy in patients with recurrent breast cancer / 2393484
Prior to begin the therapy, the patient's blood is tested for oestradiol concentration. If the concentration is 18.40 to 29.40 nmol/l, tumour size loss after the neoadjuvant automyelochemotherapy by 67-70% is predicted, that is a partial regress of the tumour, while oestradiol concentration 208.50 to 1541.0 nmol/l enables to predict the tumour size loss by 5-45% that is process stabilisation.
 Method of immunoassay for analyte detection in sample / 2420740
Ferric (III) hexacyanferrate (II) hydrosol conjugated with antibodies (antigens) to a required analyte is used as a disperse phase. The presence of the analyte is detected by observing a bright blue strip on an analytical membrane.
Method of producing biospecific polymer sorbent for extracting proteinase / 2420739
In order to produce a biospecific polymer sorbent for extracting proteinase, an aqueous solution undergoes radical polymerisation, where said solution contains 0.1-1.5 wt % ovomucoid from duck egg albumen, acylated with acyl chloride of acrylic or methacrylic acid, 7.0-20.0 wt % hydrophilic monomer consisting of acrylamide, methacrylamide or N-vinylpyrrolidon, and 0.7-15.0 bifunctional cross-linking agent. The hydrophilic monomer is further mixed with N-ethylbromide dimethylaminoethyl methacrylate, taken in amount of 45-55 wt % with respect to weight of the hydrophilic monomer.
 Method for immunohistochemical staining of cryostat tissue sections under conditions of intraoperative diagnosis / 2419798
Tissue sections are incubated simultaneously with mixed primary and secondary antibodies. Primarily, the primary antibodies are applied on the tissues, and in 15 seconds of the incubation process - the secondary antibodies without washing with a buffer. It is followed with combined incubation for 4 minutes. A substrate-chromogen solution for the incubation is prepared immediately before the application, the sections are washed with a buffer solution and distilled water heated to temperature 37°C.
Method of streptomycin detection by means of piezoelectric immunosensor / 2419797
Invention describes a method of immunochemical streptomycin detection wherein on a surface of a piezoelectric immunosensor, a receptor coating with a streptomycin-protein (bovine serum albumin) conjugate is immobilised, a settled number of streptomycin antibodies is added to a sample and kept for 2-3 min to produce an immune complex which is introduced in a cell in a phosphate buffer solution of pH = 7.1-7.5 and to record the sensor oscillation frequency variations when reacting with the streptomycin-protein conjugate with streptomycin antibodies, an analytical signal is inversely proportional to the concentration of streptomycin in the analysed sample, while the concentration is derived from the calibration chart, the receptor coating is regenerated by applying 0.03 mM potassium thiocyanate solution on the surface.
Method for enzymatic hydrolysis of proteins immobilised on substrate of scanning probe microscope / 2419796
Specific enzymatic hydrolysis of proteins immobilised on a substrate surface of a scanning probe microscope is enabled by the fact that proteins are exposed to ultrasound and a site-specific enzyme in a buffer solution of such pH value and temperature to ensure enzyme activity. Before the enzymatic hydrolysis, the substrate of the scanning probe microscope is immersed in 1-5% acetic acid and exposed to high-frequency ultrasound 1-3 MHz and power 1 Wt/cm2 and more at such temperature of the solution to ensure breaking of the protein-surface bonds. Then, the solution containing desorbed proteins is frozen and lyophilised. The substrate of the scanning probe microscope may consist of silicon, glass, mica, sapphire. The substrate surface of the scanning probe microscope whereon protein molecules are activated, is chemically activated by silane.
Method of diagnosing reproductive function in men / 2419097
Patient's blood serum is analysed by ELIZA, determining concentrations of antibodies, specific to components of male reproductive tissues. As components of male reproductive tissues, used is nuclear antigen of pachytene spermatocytes of rodents. If values of antibody concentration, expressed in units of optic density, equals or is higher than 0.37, presence of reproductive dysfunction in men is diagnosed.
 Method and set for immune-enzyme assay of functional activity of human complement component c3 / 2417375
Pharmaceutical preparation derinate representing sodium deoxyribonucleate is sorbed in microplate wells. Then, an analysed sample containing a component C3 of unknown activity and a solution of reagent R3 (component C3 activity deficient human blood serum) is added in the wells. It is followed with incubation, and after washing and drying of the dish, a conjugate of enzyme with component C3 antibodies and a substratum of this enzyme are added into the wells. The component C3 activity is evaluated by the amount of the prepared product of enzymatic reaction. A kit comprises a flat-bottomed microplate with sorbed derinate, the conjugate of enzyme with human complement component C3 antibodies, the reagent R3 (component C3 activity deficient human blood serum) and the substrate buffer.
Method and set for immune-enzyme assay of functional activity of human complement component c3 / 2417375
Pharmaceutical preparation derinate representing sodium deoxyribonucleate is sorbed in microplate wells. Then, an analysed sample containing a component C3 of unknown activity and a solution of reagent R3 (component C3 activity deficient human blood serum) is added in the wells. It is followed with incubation, and after washing and drying of the dish, a conjugate of enzyme with component C3 antibodies and a substratum of this enzyme are added into the wells. The component C3 activity is evaluated by the amount of the prepared product of enzymatic reaction. A kit comprises a flat-bottomed microplate with sorbed derinate, the conjugate of enzyme with human complement component C3 antibodies, the reagent R3 (component C3 activity deficient human blood serum) and the substrate buffer.
 Method of early tuberculosis diagnostics in hiv-infection / 2416801
Method of early tuberculosis diagnostics in HIV-infection involving immunologic marker monitoring by immune-enzyme assay is used to describe a complex of serum cytokines: tumour necrosis factor alpha, interleukin - 10 and a soluble receptor interleukin - 6 to fix the level, and while observing certain values of immunological markers, tuberculosis is diagnosed in the HIV-infected patients.
Method of human blood serum analysis for soluble form of antigen cd50 dimer / 2416800
Invention refers to a method of human blood serum analysis for a soluble form of antigen CD50 dimer involving the use of CD50-specific monoclonal antibodies whereat a tray reaction includes tetramethyl benzidine as a substratum.
Diagnostic technique for ophthalmoscopically negative retinal oedema / 2417748
Invention relates to medicine, in particular to ophthalmology. A retina is coated with a coagulate with using a laser pulse of wave length 0.81 mcm, power 5 to 100 mV, exposure time 0.1-0.2 s and spot diametre 200-300 mcm. The presence of ophthalmosopically negative retinal oedema is indicated by dark border surrounded coagulate, and the manifestation degree is shown by the dark border width: up to 1 mm - degree I oedema, 1 to 2 mm - degree II oedema, 2 to 3 mm - degree III oedema.
|
FIELD: medicine. SUBSTANCE: invention relates to field of medicine, namely to endocrinology. The following data are determined: cause of menopause, application of estrogen preparations, value of index of body weight and thyroid gland volume, concentration of antibodies to thyroid peroxidase and thyrotropic hormone. On the basis of obtained data prognostic coefficient which makes it possible to predict presence or absence of risk of developing thyroid gland diseases in the nearest five years is calculated. EFFECT: method makes it possible to determine risk of thyroid gland diseases in women of perimenopausal age, which will make it possible for a doctor of any specialty to select the most optimal way of said pathology prevention and treatment. 3 ex
The invention relates to medicine, namely to endocrinology, and can be used by doctors of other specialties. In the perimenopausal period is observed relatively high prevalence of thyroid diseases. But the diagnosis of this pathology in women in this period is extremely difficult, given the similarity of symptoms of thyroipathies have been looked into with age-related changes, mutual masking with manifestations of the climacteric syndrome. During perimenopause, the combination of high prevalence of thyroid disease in women after 45 years of estrogen deficiency, especially after surgical menopause, increases the risk of cardiovascular disease. Consequently, this requires a more thorough examination of women in the perimenopausal age for early detection, treatment and prevention of diseases of the thyroid gland that will improve health, prevent the development of manifest clinical forms of thyroid diseases and improve the quality of life for patients older than 45 years. The level of technology Analogs In the works[1, 2, 3, 4, 5, 6] we studied the risk factors, pathogenesis and diagnosis of thyroid disease, including perimenopausal, but not determined the effect of the causes of menopause on the development of thyroid pathology. Prototype In [7] to study what are the risk factors pathogenesis, diagnosis, treatment and prevention of thyroid cancer in women after menopause, however, not proposed a method for predicting the risk of development of thyroid disease in women of perimenopausal age. The INVENTION The aim of the invention is to develop a method for predicting the risk of thyroid disease in women 45-55 years. This goal is achieved by calculating a prognostic index, resulting in possible to conclude whether the patient's risk of developing thyroid cancer in the next five years or not. The method is as follows. During the history taking women 45-55 years ask, came after her menopause, and specify its cause (natural or surgical), as to whether it accepts preparations containing estrogens, when viewed measured her height and weight and calculate body mass index (BMI) using the formula: BMI = weight in kilograms/(height in meters)2. To determine the functional status of the thyroid gland determine the concentration of thyroid stimulating hormone (TSH) and antibodies to thyroid peroxidase (at-TPO) in serum enzyme-linked immunosorbent assay (ELISA) using test systems company "Alkor Bio" (S.-Petersburg, Russia) for TSH, the company "Biomerica (USA) for at-TPO and semi-automated analyzers Mltisken MCC/340, Labsystems, Finland) and Victor2(company Wallac, Finland) (normal values TTT=to 0.4 to 4.0 mIU/l, at-TPO=0-40 IU/ml). The sampling of venous blood is carried out in the morning before a meal. To assess the size, structure, presence of thyroid nodules spend her ultrasound investigation (USI) on the device Diagnostic Ultrasound System 3535 (firm&K Medical, Denmark) linear sensor 8 MHz with color Doppler mapping. Volume of a thyroid gland are calculated according to the formula Brunn J. (1981): volume = k·(T1·W1·D1+T2·W2·D2), where k = 0,479 - factor ellipsoidal, T - thickness, W - width, L is the length of the lobes. The volume of the gland to 18 ml regard as the appropriate norm. And on the basis of the obtained data to calculate a prognostic index F risk of development of diseases of the thyroid gland by the formula: F=-0,372·P1+in 0.288·P2+1,879·P3+0,397·P4+0,084·P5+0,382·P6-6,918, where P1 is the cause of menopause, if you are premenopausal or natural menopause, then P1 = 0, if surgical menopause (panhysterectomy), then P1 = 1, P2 - the volume of the thyroid gland (ml) P3 - concentration of antibodies to thyroid peroxidase (at-TPO) in the blood (IU/ml), if the at-TPO > normal, P3 = 1, if the at-TPO ≤ norm, P3 = 0, P4 - the concentration of thyroid stimulating hormone (TSH) in the blood (mIU/l) P5 - body mass index (BMI)BMI = weight in kilograms / (height in meters)2, P6 - taking medication, sod is rasih estrogens, if accepts, then P6 = 1, if not, P6 = 0, Const=-6,918. If the value of the derived index F is greater than zero, then predict an increased risk of developing thyroid cancer in the next five years, and if the value of F is less than zero, then make a conclusion about the absence of this risk to the patient. The specificity of the method is 75,25%, sensitivity - 68,4%, efficiency -74,2%. Example 1. Patient T., 50 years old, pre-menopausal women. In the past year is taking medication "klimonorm" about climacteric syndrome of moderate severity. Ultrasound examination of thyroid gland volume 16 ml, echostructure homogeneous, normal echogenicity. Thyroid function is normal (TSH = 1,8 mIU/l), the titer of at-TPO increased (at-TPO =to 163.1 IU/ml). BMI = 29.6 kg/m2. Thus, P1 = 0, P2 = 16, P3 = 1, P4 = 1,8, P5 = 29,6, P6 = 1. We will substitute the data into the formula for predicting the risk of thyroid cancer: F=-0,372·0+0,288·16+1,879·1+0,397·1,8+0,084·29,6+0,382·1-6,918=3,15. The result is greater than zero, therefore, it is possible to judge the presence of this patient's risk of thyroid disease in the next five years. After four years at the annual examination in this patient was diagnosed hypothyroidism. Therefore, the prediction was correct. Example 2. Patient C., 52 years, surgical menopause - 1 month. The estrogens are not accepted. Complaints from Sch is Coveney gland no. Ultrasound examination volume of a gland of 14.5 ml, in both lobes are education about 4 mm in diameter. Thyroid function is normal (TSH = 1,1 mIU/l), the titer of at-TPO modestly increased (at-TPO = 47,5 IU/ml). BMI = 28 kg/m2. Thus, P1 = 1, P2 = 14,5, P3 = 1, P4 = 1,1, P5 = 28, P6=0. We will substitute the data into the formula to predict the risk of development of thyroid cancer: F=-0,372·1+0,288·14,5+1,879·1+0,397·1,1+0,084·28+0,382·0-6,918=1.55V. The result is greater than zero, therefore, it is possible to judge the presence in the patient of the risk of thyroid disease in the next five years. After a year at the annual examination in this patient was diagnosed diffuse endemic goiter. Therefore, the prediction was correct. Example 3. Patient B., 50 years of pre-menopausal women. The estrogens are not accepted. Ultrasound examination gland volume = 11,2 ml Thyroid function normal (TSH = 2,1 mIU/l), the titer of at-TPO is not increased (at-TPO = 10,5 IU/ml). BMI = 20,8 kg/m2. Thus, P1 = 0, P2 = 11,2, P3 = 0, P4 = 2,1, P5 = 20,8, P6 = 0. We will substitute the data into the formula to calculate the prognostic index risk of thyroid cancer: F=-0,372·0+0,288·11,2+1,879·0+0,397·2,1+0,084·20,8+0,382··0-6,918=-1,11. The result is less than zero, therefore, it is possible to judge about the absence of risk of thyroid cancer in this patient. During 5 years of observation of the patient thyroid pathology it is not revealed. Sledovat is Ino, the forecast was correct. Thus, the proposed method allows to predict the risk of developing thyroid disease in women of perimenopausal age within 5 years, or to judge the absence of such risk, which gives the doctor an opportunity to choose the most optimal way to prevent this disease. Sources of information 1. Diseases of the thyroid gland. TRANS. from English. Ed. Lieberman. - M.: Medicine. - 2000. - 432 S.: ill. 2. Melnichenko G.A., Berketova T.U., Magefilename E.A. and other Clinical features of the course of the menopause in women with diffuse toxic goiter and primary hypothyroidism // Menopause. - 2001. No. 3. - P.55. 3. Fadeev V.V., Melnichenko G.A. Hypothyroidism: a guide for physicians. - M.: RCT Sovero press, 2002. - 216 C. 4. Arai T., S. Kurashima, Utsuyama M, et al. Measurement of anti-increase and anti-antibodies. wash buffer using a highly sensitive radioimmunoassay: an effective method for detecting asymptomatic focal lymphocytic thyroiditis in the elderly // Endocr. J. - 2000. - Vol.47, No. 5. - P.575-582. 5. Hak A.E., H.A. Pols, T.J. Visser et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study // Ann. Intern Med. - 2000. - Vol.132. - P.270-278. 6. Knudsen N., I. Bulow, T. Jorgensen et al. Comparative study of thyroid function and types of thyroid dysfunction in two areas in Denmark with slightly different iodine status // Eur. J. Endocrinol. - 2000. - Vol. 143. - P.485-491. 7. Vanderpump M., Tunbridge W., J. French et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey // Clin. Endocrinol. (Oxf) - 1995. - Vol. 43. - P.55-68. a Method for predicting the risk of disease of the thyroid gland in women of perimenopausal age, characterized in that on the basis of data about the cause of menopause, use of estrogens, the value of body mass index, volume of the thyroid gland, the concentration of antibodies to thyroid peroxidase and thyroid-stimulating hormone calculate prognostic index F by the formula F=-0,372·P1+in 0.288·P2+1,879·P3+0,397·P4+0,084·P5+0,382·P6-6,918,
|